 ROCKVILLE, Md.--BUSINESS WIRE--GlycoMimetics Nasdaq: GLYC today in an oral presentation at the 62nd American Society of Hematology ASH Annual Meeting and Exposition disclosed new data reinforcing a now comprehensive set of findings that underscore the improvement of rivipansel when administered early during an acute vaso-occlusive crisis VOC in individuals with sickle cell disease SCD. The new data were part of an analysis of an Open Label Extension OLE trial of rivipansel, designed 